Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Dafni

Showing results (41-50 of 71) with videos related to

Pageof 8
Sort By:
Lung Cancer (Amsterdam, Netherlands)|June 23, 2020
Survival outcome of non-small cell lung cancer patients: Comparing results between the database of the Comprehensive Cancer Center Zürich and the Epidemiological Cancer Registry Zurich and ZugR A Stahel, A Curioni-Fontecedro, S Rohrmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2001
Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: a randomized study conducted by the Hellenic Cooperative Oncology GroupG Fountzilas, C Papadimitriou, U Dafni, et al.
Oncology|April 15, 2000
Fluorouracil and leucovorin with or without interferon alfa-2a as adjuvant treatment, in patients with high-risk colon cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology GroupG Fountzilas, A Zisiadis, U Dafni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 12, 1999
Postoperative radiation and concomitant bolus fluorouracil with or without additional chemotherapy with fluorouracil and high-dose leucovorin in patients with high-risk rectal cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology GroupG Fountzilas, A Zisiadis, U Dafni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 23, 2006
Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology GroupG Fountzilas, P Papakostas, U Dafni, et al.
ESMO Open|March 4, 2023
Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicinesG Zarkavelis, A L Amylidi, C Verbaanderd, et al.
British Journal of Cancer|November 6, 2008
Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) studyA K Koutras, K T Kalogeras, M-A Dimopoulos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 9, 2012
Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03)A Bamias, U Dafni, A Karadimou, et al.
Breast Cancer Research and Treatment|May 17, 2008
A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group studyG Fountzilas, U Dafni, M A Dimopoulos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 14, 2006
Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapyV Malamou-Mitsi, H Gogas, U Dafni, et al.
Pageof 8

Showing results (41-50 of 71) with videos related to

Sort By:
Pageof 8
Lung Cancer (Amsterdam, Netherlands)|June 23, 2020
Survival outcome of non-small cell lung cancer patients: Comparing results between the database of the Comprehensive Cancer Center Zürich and the Epidemiological Cancer Registry Zurich and ZugR A Stahel, A Curioni-Fontecedro, S Rohrmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2001
Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: a randomized study conducted by the Hellenic Cooperative Oncology GroupG Fountzilas, C Papadimitriou, U Dafni, et al.
Oncology|April 15, 2000
Fluorouracil and leucovorin with or without interferon alfa-2a as adjuvant treatment, in patients with high-risk colon cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology GroupG Fountzilas, A Zisiadis, U Dafni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 12, 1999
Postoperative radiation and concomitant bolus fluorouracil with or without additional chemotherapy with fluorouracil and high-dose leucovorin in patients with high-risk rectal cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology GroupG Fountzilas, A Zisiadis, U Dafni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 23, 2006
Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology GroupG Fountzilas, P Papakostas, U Dafni, et al.
ESMO Open|March 4, 2023
Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicinesG Zarkavelis, A L Amylidi, C Verbaanderd, et al.
British Journal of Cancer|November 6, 2008
Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) studyA K Koutras, K T Kalogeras, M-A Dimopoulos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 9, 2012
Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03)A Bamias, U Dafni, A Karadimou, et al.
Breast Cancer Research and Treatment|May 17, 2008
A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group studyG Fountzilas, U Dafni, M A Dimopoulos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 14, 2006
Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapyV Malamou-Mitsi, H Gogas, U Dafni, et al.
Pageof 8